CME Credit: 0.25 hour activities
Epilepsy affects some 2.3 million adults and 467,711 children in the United States. Selecting the best drug for a particular patient and for a specific seizure type can be challenging for clinicians. Evidence based recommendations on the efficacy, tolerability, and safety of several AEDs were developed in 2004. Since this publication, new agents and data have emerged. Concurrently, optimal treatment designs for trials have been brought into question and new study designs developed. The regulatory requirements for the EU and the US vary substantially and their trial outcomes do not directly correlate to clinical application. There is an urgent need for education on the safe and appropriate interpretation and application of trial data to clinical practice.